Estado de HER2 (tumores sólidos — puntuación gástrica/GEJ/CRC)
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BIO-HER2-SOLID |
|---|---|
| Tipo | Biomarcador |
| Aliaces | ERBB2HER-2/neuHER2 IHC + ISHСтатус HER2 (солідні пухлини) |
| Situación | de la Convención, revisados en 2026-04-26 |
| Enfermedades | DIS-BREAST DIS-CHOLANGIOCARCINOMA DIS-CRC DIS-ESOPHAGEAL DIS-GASTRIC DIS-NSCLC DIS-SALIVARY |
| Fuentes | SRC-ESMO-GASTRIC-2024 SRC-NCCN-COLON-2025 SRC-NCCN-GASTRIC-2025 |
Datos sobre biomarcadores
| Tipo de biomarcador | protein_expression_ihc |
|---|---|
| Medición | MétodoIHC (4B5 / HercepTest), reflejo ISH (FISH/CISH/SISH) para IHC 2+. La puntuación de los tumores sólidos utiliza criterios gástricos (Hofmann 2008) — tinción membranosa basolateral / lateral ≥10% (vs mama 2018 ASCO/CAP). UnidadesIHC 0 | 1+ | 2+ | 3+; ISH HER2/CEP17 ratio with cutoff ≥2.0 |
| Productos químicos y químicos | Ninguna declarada |
Utilizado por
Relevancia terapéutica
BMA-HER2-AMP-CHOLANGIO- Cáncer del tracto biliar amplificado con HER2 (~5-15% en total; enriquecido en vesícula biliar + extrahepa...BMA-HER2-AMP-CRC- Cáncer colorrectal metastásico amplificado con HER2 (~3-5% en la población de RAS/BRAF-WT): tucatinib...BMA-HER2-AMP-ESOPHAGEAL- Adenocarcinoma esofágico HER2 positivo/GEJ marcado por criterios gástricos: trastuzumab + que...BMA-HER2-AMP-GASTRIC- Adenocarcinoma gástrico HER2 positivo/GEJ (~15-20%): trastuzumab + quimioterapia es...
Algoritmos
ALGO-ESOPH-METASTATIC-1L- ALGO-ESOPH-METASTATIC-1L
Biomarcador
BIO-CLDN18-2- Claudin-18.2 (CLDN18.2)BIO-ESTROGEN-RECEPTOR- Receptor de estrógeno (RE)BIO-FGFR2B-IHC- FGFR2b expresión de proteínas por IHC (tinción membranosa)BIO-HER2-LOW- HER2 bajo (pecho IHC 1+ o IHC 2+ ISH negativo)BIO-HER2-ULTRALOW- HER2-ultralow (pecho — IHC > 0 < 1+; mancha de membrana débil/incompleta ≤10%)
Enfermedad
DIS-CHOLANGIOCARCINOMA- Colangiocarcinoma (cáncer del conducto biológico)DIS-SALIVARY- Carcinoma de la glándula saliva
Capítulos del Manual
HB-BREAST-HER2-POS-MET-1L- Cáncer de mama metastásico HER2+: razonamiento de primera líneaHB-BREAST-HR-POS-HER2-NEG-1L- HR+/HER2- metastatic breast cancer: first-line reasoning
Indicación
IND-BREAST-BRCA-MET-TALAZOPARIB- IND-BREAST-BRCA-MET-TALAZOPARIBIND-BREAST-BRCA-POS-MET-PARPI- IND-BREAST-BRCA-POS-MET-PARPIIND-BREAST-HER2-LOW-2L-DATO-DXD- IND-BREAST-HER2-LOW-2L-DATO-DXDIND-BREAST-HER2-POS-3L-TUCATINIB- IND-BREAST-HER2-POS-3L-TUCATINIBIND-BREAST-HER2-POS-EARLY-NEOADJUVANT- IND-BREAST-HER2-POS-EARLY-NEOADJUVANTIND-BREAST-HER2-POS-MAINT-TRAST- IND-BREAST-HER2-POS-MAINT-TRASTIND-BREAST-HER2-POS-MET-1L-THP- IND-BREAST-HER2-POS-MET-1L-THPIND-BREAST-HER2-POS-MET-2L-TDXD- IND-BREAST-HER2-POS-MET-2L-TDXDIND-BREAST-HR-POS-1L-INAVOLISIB- IND-BREAST-HR-POS-1L-INAVOLISIBIND-BREAST-HR-POS-2L-AKT-CAPIVASERTIB- IND-BREAST-HR-POS-2L-AKT-CAPIVASERTIBIND-BREAST-HR-POS-2L-DATO-DXD- IND-BREAST-HR-POS-2L-DATO-DXDIND-BREAST-HR-POS-2L-ESR1-ELACESTRANT- IND-BREAST-HR-POS-2L-ESR1-ELACESTRANTIND-BREAST-HR-POS-2L-FUL-EVEROLIMUS- IND-BREAST-HR-POS-2L-FUL-EVEROLIMUSIND-BREAST-HR-POS-2L-PIK3CA-ALPELISIB- IND-BREAST-HR-POS-2L-PIK3CA-ALPELISIBIND-BREAST-HR-POS-2L-T-DXD-HER2-LOW- IND-BREAST-HR-POS-2L-T-DXD-HER2-LOWIND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKT- IND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKTIND-BREAST-HR-POS-EARLY-ADJ-CDK46I- IND-BREAST-HR-POS-EARLY-ADJ-CDK46IIND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB- IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIBIND-BREAST-HR-POS-MAINT-CDK46I- IND-BREAST-HR-POS-MAINT-CDK46IIND-BREAST-HR-POS-MET-1L-CDKI- IND-BREAST-HR-POS-MET-1L-CDKIIND-BREAST-TNBC-2L-BRCA-OLAPARIB- IND-BREAST-TNBC-2L-BRCA-OLAPARIBIND-BREAST-TNBC-2L-BRCA-TALAZOPARIB- IND-BREAST-TNBC-2L-BRCA-TALAZOPARIBIND-BREAST-TNBC-2L-DATO-DXD- IND-BREAST-TNBC-2L-DATO-DXDIND-BREAST-TNBC-2L-SACITUZUMAB- IND-BREAST-TNBC-2L-SACITUZUMABIND-BREAST-TNBC-2L-T-DXD-HER2-LOW- IND-BREAST-TNBC-2L-T-DXD-HER2-LOWIND-BREAST-TNBC-3L-POST-SACI-POST-T-DXD- IND-BREAST-TNBC-3L-POST-SACI-POST-T-DXDIND-BREAST-TNBC-EARLY-NEOADJUVANT- IND-BREAST-TNBC-EARLY-NEOADJUVANTIND-CHOLANGIO-2L-HER2-ZANIDATAMAB- IND-CHOLANGIO-2L-HER2-ZANIDATAMABIND-CRC-METASTATIC-2L-HER2-AMP-T-DXD- IND-CRC-METASTATIC-2L-HER2-AMP-T-DXDIND-CRC-METASTATIC-2L-HER2-AMP-TUCATINIB- IND-CRC-METASTATIC-2L-HER2-AMP-TUCATINIBIND-ESOPH-METASTATIC-1L-HER2-TRASTUZUMAB-CHEMO- IND-ESOPH-METASTATIC-1L-HER2-TRASTUZUMAB-CHEMOIND-ESOPH-METASTATIC-2L-HER2-POSITIVE-T-DXD- IND-ESOPH-METASTATIC-2L-HER2-POSITIVE-T-DXDIND-ESOPH-OLIGOMET-SYSTEMIC-PLUS-LOCAL- IND-ESOPH-OLIGOMET-SYSTEMIC-PLUS-LOCALIND-GASTRIC-METASTATIC-1L-CLDN18-2-ZOLBETUXIMAB- IND-GASTRIC-METASTATIC-1L-CLDN18-2-ZOLBETUXIMABIND-GASTRIC-METASTATIC-1L-FGFR2B-BEMARITUZUMAB- IND-GASTRIC-METASTATIC-1L-FGFR2B-BEMARITUZUMABIND-GASTRIC-METASTATIC-1L-HER2-TOGA- IND-GASTRIC-METASTATIC-1L-HER2-TOGAIND-GASTRIC-METASTATIC-1L-PDL1-CHEMO-ICI- IND-GASTRIC-METASTATIC-1L-PDL1-CHEMO-ICIIND-GASTRIC-METASTATIC-2L-HER2-TDXD- IND-GASTRIC-METASTATIC-2L-HER2-TDXDIND-GASTRIC-METASTATIC-2L-RAMUCIRUMAB-PACLITAXEL- IND-GASTRIC-METASTATIC-2L-RAMUCIRUMAB-PACLITAXELIND-GASTRIC-OLIGOMET-SYSTEMIC-PLUS-LOCAL- IND-GASTRIC-OLIGOMET-SYSTEMIC-PLUS-LOCAL- ... 2 más
Cuestionarios
QUEST-BREAST-1L-STUB- Cáncer de mama invasivo: primera líneaQUEST-CRC-1L-STUB- Carcinoma colorrectal — primera líneaQUEST-GASTRIC-1L-STUB- Adenocarcinoma de unión gastroesofágica y gastroesofágica - primera líneaQUEST-NSCLC-1L-STUB- Non-small cell lung cancer — first line
Señal de alerta
RF-BREAST-HIGH-RISK-BIOLOGY- mutación germlina o somática BRCA1/2, mutación PIK3CA, mutación ESR1, amplificación HER2,...RF-CHOLANGIOCARCINOMA-HIGH-RISK-BIOLOGY- Alteración molecular activa en colangiocarcinoma — fusión FGFR2 / reajuste, IDH...RF-CRC-HER2-AMP-ACTIONABLE- Amplificación de HER2 en cáncer colorrectal metastásico - IHC 3+ O (IHC 2+ E ISH amplificados,...RF-SALIVARY-HIGH-RISK-BIOLOGY- Carcinoma de la glándula saliva con controlador molecular activable: fusión ETV6-NTRK3 (aná...
Pruebas
TEST-HER2-IHC-FISH- HER2 IHC + reflejo FISH en el tumor